Australia markets open in 35 minutes

Keymed Biosciences Inc. (2162.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
33.950+0.450 (+1.34%)
At close: 04:08PM HKT
Show:
Balance sheet
Cash flow
Annual

Income statement

Currency in CNY. All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
354,095
354,095
100,063
110,269
0
Cost of revenue
36,878
36,878
2,585
17,200
0
Gross profit
317,217
317,217
97,478
93,069
0
Operating expenses
Research development
596,282
596,282
507,374
358,156
127,400
Selling general and administrative
177,006
177,006
133,912
92,454
21,548
Total operating expenses
752,017
752,017
575,742
464,388
135,467
Operating income or loss
-434,800
-434,800
-478,264
-371,319
-135,467
Interest expense
17,259
17,259
8,219
11,133
14,309
Income before tax
-356,188
-356,188
-303,597
-3,892,632
-818,848
Income tax expense
1,597
1,597
0
0
0
Income from continuing operations
-357,785
-357,785
-303,597
-3,892,632
-818,848
Net income
-359,357
-359,357
-308,115
-3,887,309
-818,583
Net income available to common shareholders
-359,357
-359,357
-308,115
-3,887,309
-818,583
Basic EPS
-1.02
-1.37
-1.18
-24.17
-3.02
Diluted EPS
-1.02
-1.37
-1.18
-24.17
-3.02
Basic average shares
260,925
261,368
261,127
160,849
270,996
Diluted average shares
260,925
261,368
261,127
160,849
270,996